medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2009, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2009; 56 (4)

Study of cortisol levels of serum from patients suffering from diabetes mellitus type 2

Mahia VM, Díaz BA, García MM, Hernández CJ, Alonso C

Language: Spanish
References: 21
Page: 257-261
PDF size: 59.15 Kb.


ABSTRACT

Background: Cortisol is the main glucocorticoid secreted by the suprarenal (adrenal) brain cortex and it is released with the purpose of acting at the peripheral tissue. When cortisol is hypersecreted in a chronic form, there may be deleterious physiological sequels, such as increases in artery blood pressure, diabetes, atherosclerosis, immunologic suppression and muscular atrophy. Objective: To determine the levels of cortisol in serum from patients suffering from diabetes mellitus type 2. Material and method: In order to determine the serum levels of cortisol, 200 diabetic patients from Cerro Municipality were included in this study. The patients were from both sexes, with ages ranging from 40 to 80 years old and with over ten years of evolution of the mentioned disease. The levels of cortisol in serum and the levels of glycemia before breakfast (unfed) were determined for these patients. Simultaneously, it was studied a non-diabetic control group belonging to the same municipality and with similar ages to the studied group of patients. Results: This present study found high levels of cortisol in the serum of the studied diabetic patients when compared to the control group. Conclusions: It was demonstrated the existence of high cortisol levels in the serum from patients with diabetes mellitus. These levels were higher in men than in women.


REFERENCES

  1. Kriegsfeld LJ, Silver R. The regulation of neuroendocrine function: Timing is everything. Hormones and Behaviour 2006; 49: 557-574.

  2. Briegel J, Sprung CL, Annane D, Singer M, Keh D et al. For the CORTICUS Study Group. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med. [serie en Internet] 2009: [citado 5 Jul. 2009]; Disponible en: http://preview.ncbi.nlm.nih.gov/pubmed?

  3. Yehuda R, Boissoneau D, Mason JW et al. Glucocorticoid receptor number and cortisol excretion in mood, anxiety and psychotic disorders. Biol Psychiatry 1993; 34: 18-25.

  4. Brillon DJ. Effect of cortisol on energy expenditure and aminoacid metabolism in humans. Am J Physiol 1995; 268: E501-E513.

  5. Sapse AT. Cortisol, high cortisol diseases and anti-cortisol therapy. Psychoneuroendocrinology 1997; 22 Suppl 1: S3-S10.

  6. Neary JP. Relationship between serum, saliva and urinary cortisol and its implication during recovery from training. J Sci Med Sport 2002; 5 (2): 108-114.

  7. Rizza RA. Cortisol-induced insulin resistance in man. J Clin Endocrinol Metab 1982; 54: 131-138.

  8. Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V et al. Cortisol secretion in patients with type 2 diabetes: Relationship with chronic complications. Diabetes Care 2007; 30 (1): 83-88.

  9. Weigensberg MJ, Toledo-Corral CM, Goran MI. Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab 2008; 93 (4): 1372-1378.

  10. Mahia M, Pérez L. La diabetes mellitus y sus complicaciones vasculares: Un problema social de salud. Rev Cub Angiol Cir Vasc 2001; 1: 68-73.

  11. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.

  12. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007; 120 (9 suppl 2): S12-S17.

  13. Matthews DR. Tsapas A. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res [serie en Internet] 2008: [citado 5 Jul 2009]; 5 (3): Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18777497?

  14. Anselmino M. Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents. J. Diabetes Complications [serie en Internet] 2008: [citado 5 Sept 2008]; Sep 1: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18768334?

  15. Socarrás SM, Blanco AJ, Vázquez VA, González HD, y Licea PM. Factores de riesgo en enfermedad aterosclerótica en la diabetes tipo 2. Rev Cub Med 2003; 42 (2): 15-22.

  16. Hayden JM and Reaven PD. Cardiovascular disease in diabetes mellitus type 2: A potential role for novel cardiovascular risk factors. Curr Opinion Lipidol 2000; 11: 519-528.

  17. Eckel RH. Perspectives on vascular biology and diabetes. J Invest Med 2001; 49 (suppl): 100-103.

  18. Vermeulen A and Van der Straden M. Determination of plasma cortisol by a fluorometric method. J Clin Endocr 1964; 24: 1188-1194.

  19. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6: 24-25.

  20. Tsigos C, Chrousos G. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psycho Res 2002; 55: 865-871.

  21. Coogan AN, Wyse CA. Neuroimmunology of the circadian clock. Brain Res. [serie en Internet] 2008: [citado 6 Sept 2008] Sep 26; 1232:104-12. Disponible en: http://www.ncbi.nlm. nih.gov/pubmed/18703032?




2020     |     www.medigraphic.com